The latest announcement follows the recent US Food and Drug Administration (FDA) acceptance of the company’s new drug ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
Missed KHOU 11+’s live Q&A on injectable PrEP? Watch on demand as experts discuss this HIV prevention breakthrough and answer ...
US antivirals giant Gilead Sciences recently announced that the US Food and Drug Administration (FDA) has accepted its New ...
6d
GlobalData on MSNGilead’s lenacapavir moves closer to FDA approval for HIV PrEP useThe US Food and Drug Administration (FDA) has accepted Gilead’s new drug application (NDA) for lenacapavir and set a ...
Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...
Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...
5d
News Medical on MSNNew HIV therapy lenacapavir shows high efficacy in Ugandan populationA multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application submissions for lenacapavir for human immunodeficiency virus (HIV) prevention.
Twice-yearly lenacapavir PrEP could be available as early as this summer pending federal Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results